Immunotherapy is revolutionizing the clinical management of multiple tumors. However, only
a fraction of patients with cancer responds to immunotherapy, and currently available …

Cancer immunotherapy and tumor microenvironment have been at the forefront of research
over the past decades. Targeting immune checkpoints especially programmed death 1 (PD …

Lymphocyte activation gene 3 (LAG-3) is a cell surface inhibitory receptor with multiple
biological activities over T cell activation and effector functions. LAG-3 plays a regulatory …

Although mesothelioma is the consequence of a protracted immune response to asbestos
fibers and characterized by a clear immune infiltrate, novel immunotherapy approaches …

Genetic engineering T cells to create clinically applied chimeric antigen receptor (CAR) T
cells has led to improved patient outcomes for some forms of hematopoietic malignancies …

Immunological therapy principles are increasingly determining modern medicine. They are
used to treat diseases of the immune system, for tumors, but also for infections, neurological …

Malignant pleural mesothelioma (MPM) is an incurable cancer with a dismal prognosis and
few effective treatment options. Nonetheless, recent positive phase III trial results for immune …

Malignant pleural mesothelioma (MPM) is a rare and fatal disease of the pleural lining. Up to
80% of the MPM cases are linked to asbestos exposure. Even though its use has been …

Natural killer (NK) cells integrate heterogeneous signals for activation and inhibition using
germline-encoded receptors. These receptors are stochastically co-expressed, and their …

Background The role of immunotherapy in cancer is now well-established, and therapeutic
options such as checkpoint inhibitors are increasingly being approved in many cancers such …